Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 4/20 | 0.40 |
| ▸ | BRD2 | P25440 | 2/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.40 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.39 |
| ▸ | NQO2 | P16083 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 5/20 | 0.38 |
| ▸ | BRD1 | O95696 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26547628 | 1.00 | MEN1 (0.43) | MEN1KMT2AL3MBTL1LMNATSHR | |
| SCHEMBL26547742 | 0.80 | BRPF1 (0.40) | MEN1KMT2AL3MBTL1LMNATSHR | |
| SCHEMBL31248987 | 0.79 | PTGS2 (0.42) | MEN1KMT2AL3MBTL1LMNABRD4 | |
| SCHEMBL30993671 | 0.79 | BRD4 (0.39) | MEN1KMT2AL3MBTL1BRD4BRD2 | |
| SCHEMBL31248925 | 0.78 | TTR (0.40) | MEN1KMT2AL3MBTL1BRD4BRD2 | |
| SCHEMBL31248669 | 0.78 | LMNA (0.46) | MEN1KMT2AL3MBTL1LMNATSHR | |
| SCHEMBL30993226 | 0.77 | BRD4 (0.37) | MEN1KMT2AL3MBTL1LMNATSHR | |
| SCHEMBL31248776 | 0.77 | BRD4 (0.37) | MEN1KMT2AL3MBTL1BRD4BRD2 | |
| SCHEMBL26547632 | 0.76 | CYP19A1 (0.43) | MEN1KMT2AL3MBTL1LMNATSHR | |
| SCHEMBL31426151 | 0.76 | NQO2 (0.53) | MEN1KMT2AL3MBTL1TSHRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025081092-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2024249888-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4210683-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | Aurigene Oncology Limited (IN) | 2023-07-19 | — | — | EP | disclosed |
| CN-116368128-A | Heterocyclic compounds as CBP/EP300 bromodomain inhibitors | 奥瑞基尼肿瘤有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022053967-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | MEN1 1342/4885KMT2A 1474/4885L3MBTL1 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.